Familial Primary Pulmonary Hypertension: Clinical Trials

99 trials for Familial Primary Pulmonary Hypertension, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

46 completed, 17 unknown, 13 recruiting, 11 terminated. 24 Not applicable, 19 Phase 2, 11 Phase 3, 8 Phase 1, 6 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable24Completed 8, Unknown 8, Recruiting 4, Enrolling by invitation 1, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 219Completed 10, Terminated 4, Unknown 2, Withdrawn 2, Recruiting 1
Phase 311Completed 6, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1
Phase 18Completed 5, Recruiting 1, Unknown 1, Withdrawn 1
Phase 46Completed 2, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1
Early Phase 12Unknown 1, Withdrawn 1

Follow Familial Primary Pulmonary Hypertension: new trials by email Literature Review of Familial Primary Pulmonary Hypertension trials Research Report on Familial Primary Pulmonary Hypertension

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
XBD173 - Pulmonary Artery Hypertension
Not applicableNot yet recruitingImperial College London62026-08-012026-03-25
Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
Virtual Reality Group - Idiopathic Pulmonary Arterial Hypertension
Not applicableEnrolling by invitationIstanbul University - Cerrahpasa322026-01-312026-04-30
EVE TRIAL , ALMA SYSTAM
Alma System - Postpartum Haemorrhage (PPH), PPH
Phase 3RecruitingResQ Medical Ltd502026-01-112026-03-30
Sotatercept in Pulmonary Arterial Hypertension
Sotatercept - Pulmonary Artery Hypertension
Phase 4RecruitingUniversity of Alberta272025-10-062026-07-09
Safety and Effectiveness of the Alma System in Treating Primary Postpartum Hemorrhage
Alma system - Postpartum Hemorrhage \(PPH\), Postpartum Hemorrhage \(Primary\)
Not applicableUnknownResQ Medical Ltd102024-09-092024-10-23
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
129Xe Hyperpolarized - Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension
Phase 2RecruitingBastiaan Driehuys202024-08-122026-02-24
Non-Invasive Measurements of Changes in Pulmonary Artery Pressure in Intensive Care Unit Patients Using Electrical Impedance Tomography - A Feasibility Study
Electrical impedance tomography - Pulmonary Artery Hypertension
RecruitingInsel Gruppe AG, University Hospital Bern282024-08-052024-11-14
REstoration of VItamin D in Pulmonary Arterial Hypertension
Calcifediol Oral Capsule, Placebo - Pulmonary Artery Hypertension, Vitamin d Deficiency
Phase 4Not yet recruitingParc de Salut Mar1022024-07-012024-02-14
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)
BALT GoldbBAL2 Detachable Balloon, Catheter System - Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Not applicableRecruitingRodrigo Ruano102024-05-012026-02-23
Potts-shunt for the Treatment of Pediatric Patients With Severe Pulmonary Hypertension
Comprehensive therapy combined Potts-shunt procedure and conventional drug therapy, Only conventional drug therapy - Pulmonary Artery Hypertension
Not applicableRecruitingChina National Center for Cardiovascular Diseases1202024-04-232024-05-28
Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)
Hyperpolarized Xe129 - Pulmonary Artery Hypertension
Phase 2WithdrawnBastiaan Driehuys2024-03-152024-01-23
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension
Qishen Yiqi Dropping Pills 0.5g Oral Three Times Daily + Targeted Therapy for Pulmonary Arterial Hypertension, Standard Pulmonary Arterial Hypertension (PAH)-Targeted Therapy Alone - Idiopathic Pulmonary Hypertension
Not applicableRecruitingGuangdong Provincial People's Hospital1202023-10-252026-05-22
High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)
6-minute walk distance (6MWD) test, 6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal) - Pulmonary Vascular Disease, Pulmonary Artery Hypertension
Not applicableUnknownUniversity of Zurich242023-09-232023-10-05
HA Residents With PVD, SDB Assessed at HA (2840m) vs LA (Sea Level)
Assessment without intervention at High altitude, Relocation to sea level for 2 days - Pulmonary Vascular Disease, Pulmonary Artery Hypertension
Not applicableUnknownUniversity of Zurich242023-09-222023-10-10
HA Residents With PVD, 6MWD Assessed at HA (2840m) vs LA (Sea Level)
Relocation to sea level - Pulmonary Vascular Disease, Pulmonary Artery Hypertension
Not applicableUnknownUniversity of Zurich242023-07-052023-10-03
HA Residents With PVD, Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) With and Without Supplemental Oxygen Therapy (SOT)
Supplemental oxygen therapy, Sham Oxygen therapy - Pulmonary Vascular Disorder, Pulmonary Artery Hypertension
Not applicableUnknownUniversity of Zurich242023-07-052023-10-16
Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific Therapy
Idiopathic Pulmonary Arterial Hypertension
UnknownRussian Cardiology Research and Production Center1502023-05-302024-09-19
Empagliflozin in Pulmonary Arterial Hypertension
Empagliflozin 10 MG - Idiopathic Pulmonary Arterial Hypertension
Phase 2CompletedAmsterdam UMC, location VUmc82023-03-012024-11-20
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
No Intervention - Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
RecruitingVanderbilt University Medical Center752023-01-172026-05-29
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
RecruitingVanderbilt University Medical Center1502022-11-012026-03-10

Showing 20 of 99. Sign in to see all of them.

Narrower conditions

Hypertension, Pulmonary (34)  ·  Pulmonary Arterial Hypertension (32)  ·  Hypertension (12)  ·  Lung Diseases (11)  ·  Connective Tissue Diseases (8)  ·  Respiratory Tract Diseases (8)  ·  Vascular Diseases (8)  ·  Cardiovascular Diseases (7)  ·  Hypoxia (5)  ·  Altitude Sickness (3)  ·  Pulmonary Disease, Chronic Obstructive (3)  ·  Rare Diseases (3)  ·  Acute Lung Injury (2)  ·  Cardiomyopathies (2)

Broader conditions

Respiratory Tract Diseases (91)  ·  Lung Diseases (88)  ·  Hypertension, Pulmonary (65)  ·  Cardiovascular Diseases (38)  ·  Vascular Diseases (32)  ·  Hypertension (27)  ·  Pathological Conditions, Signs and Symptoms (21)  ·  Pathologic Processes (14)  ·  Skin and Connective Tissue Diseases (11)  ·  Disease Attributes (8)  ·  Respiration Disorders (8)  ·  Heart Diseases (7)  ·  Signs and Symptoms (6)  ·  Signs and Symptoms, Respiratory (6)  ·  Chronic Disease (5)

Interventions

Iloprost (5)  ·  Sodium Chloride (3)  ·  CXA-10 (2)  ·  Oxygen (2)  ·  ambrisentan (2)  ·  cyclo(Trp-Asp-Pro-Val-Leu) (2)  ·  ralinepag (2)  ·  ACE-011 (1)  ·  Acetylcholine (1)  ·  Albuterol (1)  ·  Angiotensin I (1)  ·  Ascorbic Acid (1)  ·  Benzbromarone (1)  ·  Bisoprolol (1)  ·  Bosentan (1)

Sponsors

Vanderbilt University Medical Center (7)  ·  University of Zurich (5)  ·  Bayer (4)  ·  Amsterdam UMC, location VUmc (3)  ·  Imperial College London (3)  ·  Liquidia Technologies, Inc. (3)  ·  United Therapeutics (3)  ·  Zhejiang University (3)  ·  Bastiaan Driehuys (2)  ·  Complexa, Inc. (2)  ·  National Center for Research Resources (NCRR) (2)  ·  National Heart, Lung, and Blood Institute (NHLBI) (2)  ·  ResQ Medical Ltd (2)  ·  Respira Therapeutics, Inc. (2)  ·  Sheffield Teaching Hospitals NHS Foundation Trust (2)

Countries

United States (38)  ·  United Kingdom (14)  ·  Germany (13)  ·  China (10)  ·  France (9)  ·  Switzerland (9)  ·  Australia (6)  ·  Netherlands (6)  ·  Spain (6)  ·  Austria (5)  ·  Belgium (5)  ·  Canada (5)  ·  Israel (5)  ·  Italy (5)  ·  South Korea (4)

Top investigators

Rodrigo Hoyos, Dr. (4)  ·  Silvia Ulrich, Prof. Dr. (4)  ·  Nicholas S Hill, MD (2)  ·  Theo Danoff, MD (2)  ·  Abbot R. Laptook, MD (1)  ·  Adaani E. Frost (1)  ·  Aiden Abidov, MD, PhD (1)  ·  Andy Swift, MD (1)  ·  Angela Sinn, Dr. (1)  ·  Anna Hemnes, MD (1)  ·  Anna R Hemnes (1)  ·  Anna R Hemnes, MD (1)  ·  Anton Vonk Noordegraaf, Prof. MD PhD (1)

Results publications

PMID 17418297, PMID 15265294, PMID 16000352, PMID 17012628, PMID 17443204, PMID 17517240, PMID 17586184, PMID 18337740, PMID 18829679, PMID 19067285, PMID 20405117, PMID 21885399, PMID 21969018, PMID 25225206, PMID 26401247, PMID 27001191, PMID 27390285, PMID 28100544, PMID 29903860, PMID 29925397, PMID 30002102, PMID 31534782, PMID 31775708, PMID 32222912, PMID 33167773, PMID 33282202, PMID 33325799, PMID 33604801, PMID 33735594, PMID 33878341, PMID 35819325, PMID 38705167, PMID 39698150, PMID 40611611, PMID 41921908, PMID 42457022, PMID 42500881, PMID 42520828, PMID 7056079

NIH funding

2004 (1), 2015 (1), 2018 (1), M01RR000032 (1), M01RR000044 (1), M01RR000070 (1), M01RR000633 (1), M01RR000750 (1), M01RR006022 (1), M01RR007122 (1), M01RR008084 (1), M01RR016587 (1), P01CA108671 (1), R01HL114910 (1), U10HD021373 (1)